What makes these three hip injections fundamentally different

Three injections come up repeatedly when hip pain reaches the stage of a specialist consultation — cortisone, hyaluronic acid, and ChondroFiller injection — yet they are not alternatives for the same problem. Each works at a different level of hip joint biology.

Cortisone is an anti-inflammatory: it damps down the chemical signals driving an acute flare. Hyaluronic acid is a lubricant: it supplements the synovial fluid that cushions the joint and wears thin in osteoarthritis. ChondroFiller injection is neither of those things — it is an injectable collagen scaffold that sets in place inside the hip joint and provides a biological matrix for the body's own cells to rebuild cartilage over the months that follow.

Because the mechanisms differ, the right patient profile differs too. Selecting the wrong injection for the wrong hip problem is a common mismatch — and one that this article, aimed at patients in Lincolnshire and surrounding areas weighing up their options, works through in detail.

ChondroFiller injection: scaffold repair for focal cartilage defects

Unlike the palliative options described above, the ChondroFiller injection works at the tissue level. Delivered as a single ultrasound-guided outpatient injection, it places a CE-marked acellular Type I collagen hydrogel directly onto the worn cartilage surface of the hip joint. Within minutes the material gels in situ, forming a stable biological scaffold. Over the following 6–12 months, the body's own progenitor cells migrate into that matrix — a process called matrix-induced chondrogenesis — and progressively rebuild cartilage tissue within the defect.

Who it suits — and who it does not

Patient selection is the single strongest determinant of outcome. ChondroFiller injection is designed for focal cartilage defects on the femoral head or acetabulum — ICRS or Outerbridge Grade II to IV — in a hip that is not otherwise globally worn. Patients with Tönnis Grade 2–3 osteoarthritis have fared poorly in published series. In one prospective hip cohort with up to 60-month follow-up, results in patients with pre-existing OA of that severity were consistently poor, whereas 17 of 21 evaluable patients with appropriately focal lesions achieved good or excellent outcomes at three to five years. ChondroFiller injection is not a substitute for hip replacement in an advanced arthritic joint; MRI staging is essential before any pathway decision is made.

Hip-specific outcomes

In hip cohort data, patients recorded a mean improvement of 33 points on the Modified Harris Hip Score alongside an approximate 6-point reduction in pain scores. MOCART MRI quality scores of 70–87 indicate consistent, high-quality cartilage fill at follow-up imaging. Across all joint sites, published evidence shows 70–85% of appropriately selected patients achieve meaningful symptom relief at three to five years, with more than 19,000 procedures performed worldwide and no serious complications reported.

Following the injection, patients typically observe partial weight-bearing for approximately six weeks to allow scaffold integration before loading is gradually restored. ChondroFiller injection is not available on the NHS for hip patients anywhere in the UK; access and cost details for Lincolnshire patients are covered in the section below.

Cortisone hip injections: fast relief for acute inflammatory flares

For acute hip pain — a sudden flare of osteoarthritis, a sharp worsening of baseline discomfort — cortisone remains the most immediately accessible option. Available on the NHS and delivered under ultrasound guidance as an outpatient procedure, it suppresses the inflammatory signals driving the flare, with most patients noticing a meaningful reduction in pain within 24–48 hours. Effects typically last between 6 and 12 weeks.

That short window is the key clinical context. A 2024 network meta-analysis of 16 RCTs involving 1,735 patients confirmed that cortisone outperforms placebo at three months for hip OA pain — but that advantage is gone by six months. A 2025 PROSPERO-registered meta-analysis reinforced this picture, finding no statistically significant benefit over placebo on WOMAC pain at two months (p=0.05) and no advantage over hyaluronic acid at six months (p=0.46).

Frequency matters as well as timing. A 2025 systematic review of 80 studies found the hip joint appears more vulnerable to corticosteroid-related cartilage damage than the knee; cumulative doses above 18–24 mg have been associated with cartilage volume loss. By contrast, single or infrequent low-dose injections showed no significant structural damage across multiple studies in that review.

Cortisone is therefore best understood as a bridge — a reliable way to control acute inflammation while a longer-term management plan, whether hyaluronic acid, cartilage-focused intervention, or rehabilitation, is put in place. It is not a cartilage-preservation strategy.

Hyaluronic acid hip injections: lubrication for mild-to-moderate OA

Hyaluronic acid (HA) viscosupplementation occupies a distinct middle ground: it neither suppresses acute inflammation like cortisone nor rebuilds damaged tissue like ChondroFiller injection. Its role is to supplement depleted synovial fluid, restoring some of the lubrication and shock absorption that a hip with mild-to-moderate osteoarthritis has progressively lost.

The onset is slower than cortisone — pain relief typically builds over three to four weeks — but the benefit tends to last longer. A 2025 Level I systematic review of 982 hip OA patients found that high-molecular-weight HA produced significantly lower VAS pain scores at four to six months compared with placebo (mean difference −1.6) and medium-molecular-weight HA (MD −1.4), with WOMAC functional improvements over control groups. That evidence base makes HA a reasonable option for patients whose hip pain is more chronic and diffuse than acutely inflamed, and where MRI has not identified a focal cartilage defect suited to scaffold repair.

Because the hip joint sits deep beneath substantial soft tissue, accurate intra-articular placement requires ultrasound or fluoroscopy guidance — standard practice at specialist MSK clinics. Treatment is typically a single injection or a series of up to three weekly injections, with a maximum of two courses per year generally advised.

HA injections are not routinely funded by the NHS for hip osteoarthritis, but they are widely accessible privately, including through MSK Doctors clinics serving the Lincolnshire area.

NHS access, private cost, and availability for Lincolnshire patients

Practical access differs considerably across the three options. Cortisone is NHS-funded and the most straightforward to arrange: a GP referral to a local musculoskeletal or radiology service covers the procedure, and it is available across Lincolnshire without going privately. Hyaluronic acid occupies a middle position — it is not routinely commissioned by the NHS for hip osteoarthritis, but it is widely available through private MSK clinics, including those serving the Lincolnshire catchment.

ChondroFiller injection sits outside NHS funding entirely. NICE has issued no technology appraisal for it in any joint indication, and the NHS hip pathway moves directly from conservative care to hip replacement, with no funded preservation step between them. That gap is a structural feature of current commissioning, not a reflection of clinical evidence. For patients who wish to explore this option, treatment is self-funded; pricing at London Cartilage Clinic ranges from £3,000 for one box to £8,000 for three, inclusive of consultation, ultrasound, and six-week follow-up — detail covered in the ChondroFiller section above, where the two-box option (£5,500) is also listed.

For Lincolnshire patients, the specialist access route for ChondroFiller injection is London Cartilage Clinic, where Professor Paul Y. F. Lee — who introduced the procedure to the UK — operates as part of the MSK Doctors group. Lincolnshire Hip is the regional patient-facing platform within that same group and accepts patients without GP referral for hip assessment.

How MRI staging points to the right injection

Choosing the right injection without current hip imaging is, in practice, guesswork — X-ray and clinical examination alone cannot reliably distinguish a focal cartilage defect from diffuse osteoarthritis, yet the two require entirely different treatment strategies.

Three MRI scenarios map fairly directly onto the injection options covered above:

Focal cartilage defect — a contained lesion with confirmed defect depth and limited surrounding damage — opens the door to ChondroFiller injection as a regenerative scaffold pathway. MRI also indicates lesion size, which governs the amount of product needed and the realistic scope of repair.

Mild-to-moderate OA with thinned but intact cartilage and early synovial fluid changes is the appropriate setting for hyaluronic acid viscosupplementation, where the goal is lubrication and cushioning rather than structural regeneration.

Acute inflammatory flare, where rapid pain reduction is the primary objective, is where cortisone remains the most practical immediate step, regardless of what the underlying imaging shows.

Where advanced diffuse OA is present — as the ChondroFiller section above covers in detail — preservation injections are unlikely to alter the structural picture; both ChondroFiller injection and HA lose their rationale at that stage, and the realistic pathway shifts toward hip replacement planning.

Patients who have not had hip-specific MRI and are weighing these three options should seek a specialist hip assessment first: the imaging is the decision tool, not the injection itself.

1. [1] Current trends in the treatment of focal cartilage lesions: a comprehensive review. (2025). https://doi.org/10.1530/EOR-2024-0083 https://doi.org/10.1530/EOR-2024-0083
2. [2] The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review. (2025). https://doi.org/10.1007/s11916-025-01378-z https://doi.org/10.1007/s11916-025-01378-z
3. [3] Pain management of hip osteoarthritis with corticosteroids vs injection therapies: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s12891-025-08666-0 https://doi.org/10.1186/s12891-025-08666-0
4. [4] A Comprehensive Systematic Review of The Relationship Between Intra-Articular Corticosteroid Use and Cartilage Damage. (2025). https://doi.org/10.70070/g9ry3s82 https://doi.org/10.70070/g9ry3s82
5. [5] Intra-articular hyaluronic acid injections for hip osteoarthritis: a level I systematic review. (2025). https://doi.org/10.1007/s00590-025-04292-7 https://doi.org/10.1007/s00590-025-04292-7
6. [6] Clinical efficacy of multiple intra-articular injection for hip osteoarthritis. (2024). https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-1272.R1 https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-1272.R1